Breeden Richard C sold $310K of STE

Breeden Richard C sold 1,481 shares of STERIS plc (STE) at $209.51 ($0.31M total) on 2026-06-02.

Original reporting
SEC EDGAR · Breeden Richard C
Published Jun 4, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STE
Neutral
high confidence
Mentioned
$STE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STENeutralLow
01

Why it matters

The disclosure updates insider activity records but does not introduce new company fundamentals (earnings, guidance, deals, litigation, or regulatory actions).

02

Market read

Primarily a sentiment/positioning datapoint for STE; likely limited trading impact absent additional catalysts.

03

What to watch

Insider sales often occur for non-informational reasons (taxes, planned diversification, personal liquidity), and the article provides no follow-on guidance or performance change.

Relevance 4/10Novelty 3/10Timing: Filed 2026-06-04; sale occurred 2026-06-02.

Background

The article is an SEC Form 4 insider transaction disclosure for STERIS plc, reported by a director.

Company-level read

Ticker impact

$STENeutralHigh confidence
Context

STERIS director Richard C Breeden sold 1,481 shares in an open-market transaction at ~$209.51 on 2026-06-02, disclosed via Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing reports a routine Form 4 sale with no 10b5-1 plan stated and no accompanying company-specific operational or financial news.

Market effects

Minimal; single-company insider transaction without sector-wide implications.

None indicated.

None indicated.

Counterpoint

Because the sale is open-market and the filing lacks a stated 10b5-1 plan, traders may overinterpret it; it could still be routine liquidity or diversification.

Key entities

  • STERIS plc

    Subject of the SEC Form 4 insider sale disclosure.

  • Breeden Richard C

    Director who sold 1,481 shares on 2026-06-02.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STEMedAI 8/10

STERIS Irish FinCo Unlimited Company, a public unlimited company incorporated under the laws of Ireland and a wholly-owned subsidiary of STERIS plc, a public…

STERIS plc (STE) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On November 9, 2026, STERIS Irish FinCo Unlimited Company, a public unlimited company incorporated under the laws of Ireland (the “Issuer”) and a wholly-owned subsidiary of STERIS plc, a public limited company incorporated under the laws of Ireland (the “C

$STEMed

What STERIS (STE) Said on Its Q2 Earnings Call

STERIS (STE) reported Q2 adjusted EBIT margin up 150 bps to 24.6%, with EPS growth of 13% excluding refunds. Life Sciences revenue rose 18%, leading to an increased full-year growth forecast of 9-10%. AST segment revenue grew 5%, but its forecast was lowered to 6-7%. The company announced a $45M restructuring plan and expects its Xodus Medical acquisition to boost revenue and margins.

$STEMed

Steris PLC (STE) (Q2 2027) Earnings Call Highlights: Revenue Climbs 9%

STERIS PLC reported Q2 2027 revenue up 9%, but EBIT margins declined in both Healthcare and AST segments due to inflation and other factors. AST revenue growth guidance was lowered. Free cash flow decreased. A $45M restructuring plan was announced. CEO Dan Carestio discussed growth opportunities, including the Xodus Medical acquisition, and addressed margin pressures and market dynamics.

$STEHighAI 8/10

STERIS (STE) Q2 2027 Earnings Call Transcript

STERIS (STE) reported Q2 2027 earnings with adjusted EBIT margin at 24.6%, up 150 bps YoY. Adjusted EPS grew 19% to $2.94. Revenue grew 7-8%, with Healthcare up 7%, AST up 5%, and Life Sciences up 18%. The company announced plans to acquire Xodus Medical. Full-year EPS outlook raised to $11.35-$11.55. Free cash flow was $492.5M for H1 2027.

$CATMedAI 8/10

Caterpillar's $1B Sanford Plant Fuels Raleigh-Durham Growth

Caterpillar plans to invest $1B in a North Carolina plant, expanding manufacturing capacity. The project is part of a broader industrial surge in Raleigh-Durham, with increased leasing activity and construction. Other companies, including AbbVie, Siemens, and Forge Nano, are also investing in the region. Research Triangle Park is diversifying with mixed-use and residential developments.